(Q30816565)

English

Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

chemoradiotherapy

0 references

clinical oncology

1 reference

based on heuristic

inferred from title

author name string

Yuichiro Ohe

1

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Naoki Ishizuka

2

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Tomohide Tamura

3

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Ikuo Sekine

4

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Yutaka Nishiwaki

5

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Nagahiro Saijo

6

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Japan Clinical Oncology Group

7

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

729-734

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01510.X

21 January 2018

Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01510.X

21 January 2018

Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan Clinical Oncology Group Study 9306.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01510.X

21 January 2018

Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01510.X

21 January 2018

A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01510.X

21 January 2018

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01510.X

21 January 2018

Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01510.X

21 January 2018

Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01510.X

21 January 2018

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2003.TB01510.X

21 January 2018

Identifiers

10.1111/J.1349-7006.2003.TB01510.X

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30816565&oldid=1954200544"